HHC and delta-9 THC are on different federal clocks. Under P.L. 119-103, the part of the new hemp redefinition that reaches cannabinoids not capable of being naturally produced by the cannabis plant starts November 12, 2026, while the rest, including the 0.4 mg total THC per container cap that governs hemp-derived delta-9, was pushed to December 11, 2026. HHC is the cannabinoid most exposed to the earlier date.
That is the short legal answer to "HHC vs THC" in late 2026. The longer answer depends on how you classify a product, because the same SKU can be affected by a DEA rule, by a state scheduling order, and by two separate federal dates at once.
HHC, or hexahydrocannabinol, is a hydrogenated cannabinoid. Commercial HHC is made in a lab by adding hydrogen to hemp-derived cannabinoids, usually starting from CBD. Delta-9 THC is the cannabinoid the 2018 Farm Bill used to define hemp, at no more than 0.3 percent on a dry-weight basis. This article makes no claims about potency or effects; those are testing and labeling questions, not legal ones.
The legal split turns on production method. Federal hemp law has long protected cannabinoids that come from the plant; it is far less clear about cannabinoids made by chemical conversion. Our piece on naturally derived versus synthesized cannabinoids covers the evidence standard for each side.
On May 4, 2026, the DEA published a final rule titled "Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance" (91 Fed. Reg. 23913; Docket DEA-1632). The rule gives HHC its own Schedule I listing, drug code 7220. In the rule, DEA says HHC was already controlled in Schedule I as a tetrahydrocannabinol under a different code, that the 2018 Farm Bill's hemp exclusion covers only THC from the plant, and that THC produced "through chemical conversion" does not qualify, even when derived from hemp. It describes the change as technical and skipped notice and comment. The rule cites the UN Commission on Narcotic Drugs' March 2025 decision to place HHC under the 1971 Convention on Psychotropic Substances.
Two hemp companies have challenged the rule: IHC Investments in the Ninth Circuit and Bluestar Operations in the Fourth. As reported by Marijuana Moment, the Fourth Circuit denied Bluestar's request for a stay in June, and the DEA's August 11 brief argues Bluestar lacks standing and that HHC is synthetic. No merits ruling has been reported. Our coverage of the HHC Schedule I lawsuit tracks the filings.
| Item | HHC | Hemp-derived delta-9 THC |
|---|---|---|
| Origin | Hydrogenated in a lab from hemp-derived cannabinoids | Occurs in the plant |
| Federal position today | DEA lists it in Schedule I (May 4, 2026 rule); challenged in two circuits | Hemp if the product meets the 0.3 percent delta-9 test; federal redefinition pending |
| November 12, 2026 | First phase reaches cannabinoids not capable of being naturally produced by the plant | Not the first-phase target |
| December 11, 2026 | Also subject to the total-THC redefinition and exclusions | 0.4 mg total THC per container cap and total-THC redefinition begin |
| State treatment | Scheduled or restricted in some states, such as South Carolina | Varies widely by state and product form |
| Testing and labels | Documentation of process and sourcing matters | Total THC per container, including THCA, matters |
The open question is who decides what counts as "not capable of being naturally produced" by the cannabis plant. We checked the FDA's cannabis regulation page, which shows content current as of July 16, 2024, and it contains no list of such cannabinoids or reference to the 2026 hemp definition. Until a list or guidance appears, the November 12 line for any specific cannabinoid rests on interpretation. The court challenges could also change the picture.
States are not following one pattern. Illinois sets its own line: from November 12 it treats consumable hemp products above 0.4 mg total THC per container as cannabis, which is one reason HHC and delta-8 sellers should read Illinois's 2026 cannabis omnibus law and the state hemp deadlines. South Carolina went the scheduling route. Abroad, HHC is treated differently again; see HHC in the UK and Europe.
For neighboring comparisons, see HHC vs delta-8, THCA vs THC, delta-8 vs delta-9 and THC-P vs THC. The federal calendar is set out in our explainer on the federal hemp dates.
HHC is a hydrogenated cannabinoid made from hemp-derived compounds; delta-9 THC occurs naturally in the plant. Their legal treatment now diverges by federal date.
Both are affected by the federal hemp redefinition. THCA counts toward total THC on December 11, while HHC is exposed to the earlier November 12 phase. State law varies.
The DEA says HHC is in Schedule I and that position is being challenged in court. Federally, the first phase of the hemp redefinition reaches cannabinoids not capable of being naturally produced from November 12, 2026, and many states restrict HHC. Check your state.
The DEA's May 2026 rule describes HHC as synthetic; the companies challenging it say it is a hemp derivative protected by the 2018 Farm Bill. A court has not resolved the question.
That is not a legal question. Potency claims belong in product testing and should not appear in marketing without counsel's review.
This is regulatory journalism, not legal advice — talk to your counsel.
